Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage
- 11 July 2008
- journal article
- research article
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 21 (4) , 457-463
Abstract
Summary: Melanoma incidence continues to rise at an alarming rate while effective systemic therapies remain very limited. Microphthalmia‐associated transcription factor (MITF) is required for development of melanocytes and is an amplified oncogene in a fraction of human melanomas. Microphthalmia‐associated transcription factor also plays an oncogenic role in human clear cell sarcomas, which typically exhibit melanoma‐like features. Although pharmacologic suppression of MITF is of potential interest in a variety of clinical settings, it is not known to contain intrinsic catalytic activity capable of direct small molecule inhibition. An alternative drug‐targeting strategy is to identify and interfere with lineage‐restricted mechanisms required for its expression. Here, we report that multiple histone deacetylase (HDAC)‐inhibitor drugs potently suppress MITF expression in melanocytes, melanoma and clear cell sarcoma cells. Although HDAC inhibitors may affect numerous cellular targets, we observed suppression of skin pigmentation by topical drug application as well as evidence of anti‐melanoma efficacy in vitro and in mouse xenografts. Consequently, HDAC inhibitor drugs are candidates to play therapeutic roles in targeting conditions affecting the melanocyte lineage.Keywords
This publication has 30 references indexed in Scilit:
- Mitf regulation of Dia1 controls melanoma proliferation and invasivenessGenes & Development, 2006
- MITF: master regulator of melanocyte development and melanoma oncogeneTrends in Molecular Medicine, 2006
- Oncogenic MITF dysregulation in clear cell sarcoma: Defining the MiT family of human cancersCancer Cell, 2006
- Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Patients With Advanced Hematologic MalignanciesJournal of Clinical Oncology, 2006
- Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced CancerJournal of Clinical Oncology, 2005
- Association of valproate‐induced teratogenesis with histone deacetylase inhibition in vivoThe FASEB Journal, 2005
- Histone deacetylase inhibitors and malignant melanomaPigment Cell Research, 2005
- Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3Blood, 2005
- β-Catenin–induced melanoma growth requires the downstream target Microphthalmia-associated transcription factorJournal of Cell Biology, 2002
- Murine Cutaneous Mastocytosis and Epidermal Melanocytosis Induced by Keratinocyte Expression of Transgenic Stem Cell FactorJournal of Experimental Medicine, 1998